Shots:
- The EC has approved Ordspono for treating r/r FL or r/r DLBCL in patients who have progressed after ≥2L of systemic therapy
- Approval was supported by Ordspono’s P-I (ELM-1; n=60) trial in patients with CD20+ B-cell malignancies, incl. those who progressed post CAR-T therapy & P-II (ELM-2; n=128) trial for 5 B-cell lymphoma subtypes such as DLBCL, FL, mantle cell lymphoma, marginal zone lymphoma
- R/R FL patients (ELM-2) had an ORR of 80% & CR in 73% (mDoR: 25mos.); r/r DLBCL patients naïve to CAR T therapy (ELM-2) had an ORR of 52% & CR in 31% (mDoR: 18mos.); r/r DLBCL patients who progressed post CAR-T therapy (ELM-1) had an ORR of 48% & CR in 32% (mDoR: 15mos.
Ref: Regeneron | Image: Regeneron| Press Release
Related News:- SIFI and Avanzanite Bioscience’s Akantior (Polihexanide) Gains the EC’s Approval to Treat Acanthamoeba Keratitis (AK)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
